The University of Southampton
University of Southampton Institutional Repository

Risk factors for severe reactions in food allergy: Rapid evidence review with meta-analysis

Risk factors for severe reactions in food allergy: Rapid evidence review with meta-analysis
Risk factors for severe reactions in food allergy: Rapid evidence review with meta-analysis
This rapid review summarizes the most up to date evidence about the risk factors for severe food-induced allergic reactions. We searched three bibliographic databases for studies published between January 2010 and August 2021. We included 88 studies and synthesized the evidence narratively, undertaking meta-analysis where appropriate. Significant uncertainties remain with respect to the prediction of severe reactions, both anaphylaxis and/or severe anaphylaxis refractory to treatment. Prior anaphylaxis, an asthma diagnosis, IgE sensitization or basophil activation tests are not good predictors. Some molecular allergology markers may be helpful. Hospital presentations for anaphylaxis are highest in young children, yet this age group appears at lower risk of severe outcomes. Risk of severe outcomes is greatest in adolescence and young adulthood, but the contribution of risk taking behaviour in contributing to severe outcomes is unclear. Evidence for an impact of cofactors on severity is lacking, although food-dependent exercise-induced anaphylaxis may be an exception. Some medications such as beta-blockers or ACE inhibitors may increase severity, but appear less important than age as a factor in life-threatening reactions. The relationship between dose of exposure and severity is unclear. Delays in symptom recognition and anaphylaxis treatment have been associated with more severe outcomes. An absence of prior anaphylaxis does not exclude its future risk.
anaphylaxis, biomarkers, food allergy, risk assessment, severity
0105-4538
2634-2652
Turner, Paul J
22cee218-a226-4300-aad1-b9a77ca65915
Arasi, Stefania
ae1cb6ec-1484-4fc9-aac6-3a18aeae18e4
Ballmer-Weber, Barbara
545f0925-62e6-4a04-acae-848d005850db
Baseggio Conrado, Alessia
fdd6bace-9427-4251-b7c5-810440e381c8
Deschildre, Antoine
0b3562a0-65e1-4e75-aba4-469371cd2c93
Gerdts, Jennifer
c09c6388-36e4-448d-8031-88b38b837759
Halken, Susanne
2d3b1100-70d1-46e1-8466-15990d478a9f
Muraro, Antonella
c554bef5-502b-4540-a6f0-a3f7c37f0075
Patel, Nandinee
a6f97da6-f563-4ab7-86c6-209228269c55
Van Ree, Ronald
f6c2aabb-0e67-4e24-b2ed-b9c30641aebc
de Silva, Debra
bebaefba-beb5-460f-acbd-9354a549dc9a
Worm, Margitta
59406574-ce5f-4ca5-9319-7543c719cc5b
Zuberbier, Torsten
0c26e302-c8de-4e14-a699-a9746692e1ff
Roberts, Graham
ea00db4e-84e7-4b39-8273-9b71dbd7e2f3
Global Allergy, Asthma European Network (GA2LEN) Food Allergy Guideline Group
Turner, Paul J
22cee218-a226-4300-aad1-b9a77ca65915
Arasi, Stefania
ae1cb6ec-1484-4fc9-aac6-3a18aeae18e4
Ballmer-Weber, Barbara
545f0925-62e6-4a04-acae-848d005850db
Baseggio Conrado, Alessia
fdd6bace-9427-4251-b7c5-810440e381c8
Deschildre, Antoine
0b3562a0-65e1-4e75-aba4-469371cd2c93
Gerdts, Jennifer
c09c6388-36e4-448d-8031-88b38b837759
Halken, Susanne
2d3b1100-70d1-46e1-8466-15990d478a9f
Muraro, Antonella
c554bef5-502b-4540-a6f0-a3f7c37f0075
Patel, Nandinee
a6f97da6-f563-4ab7-86c6-209228269c55
Van Ree, Ronald
f6c2aabb-0e67-4e24-b2ed-b9c30641aebc
de Silva, Debra
bebaefba-beb5-460f-acbd-9354a549dc9a
Worm, Margitta
59406574-ce5f-4ca5-9319-7543c719cc5b
Zuberbier, Torsten
0c26e302-c8de-4e14-a699-a9746692e1ff
Roberts, Graham
ea00db4e-84e7-4b39-8273-9b71dbd7e2f3

Turner, Paul J, Arasi, Stefania, Ballmer-Weber, Barbara, Baseggio Conrado, Alessia, Deschildre, Antoine and Gerdts, Jennifer , Global Allergy, Asthma European Network (GA2LEN) Food Allergy Guideline Group (2022) Risk factors for severe reactions in food allergy: Rapid evidence review with meta-analysis. Allergy, 77 (9), 2634-2652. (doi:10.1111/all.15318).

Record type: Review

Abstract

This rapid review summarizes the most up to date evidence about the risk factors for severe food-induced allergic reactions. We searched three bibliographic databases for studies published between January 2010 and August 2021. We included 88 studies and synthesized the evidence narratively, undertaking meta-analysis where appropriate. Significant uncertainties remain with respect to the prediction of severe reactions, both anaphylaxis and/or severe anaphylaxis refractory to treatment. Prior anaphylaxis, an asthma diagnosis, IgE sensitization or basophil activation tests are not good predictors. Some molecular allergology markers may be helpful. Hospital presentations for anaphylaxis are highest in young children, yet this age group appears at lower risk of severe outcomes. Risk of severe outcomes is greatest in adolescence and young adulthood, but the contribution of risk taking behaviour in contributing to severe outcomes is unclear. Evidence for an impact of cofactors on severity is lacking, although food-dependent exercise-induced anaphylaxis may be an exception. Some medications such as beta-blockers or ACE inhibitors may increase severity, but appear less important than age as a factor in life-threatening reactions. The relationship between dose of exposure and severity is unclear. Delays in symptom recognition and anaphylaxis treatment have been associated with more severe outcomes. An absence of prior anaphylaxis does not exclude its future risk.

Text
Allergy - 2022 - Turner - Risk factors for severe reactions in food allergy Rapid evidence review with meta‐analysis - Version of Record
Available under License Creative Commons Attribution.
Download (2MB)

More information

Accepted/In Press date: 17 April 2022
e-pub ahead of print date: 20 April 2022
Published date: September 2022
Additional Information: Funding Information: This review was conducted as part of the development of food allergy guidelines for GA2LEN, where contributors volunteered their time. This research was part-funded by the UK Medical Research Council (grant references MR/K010468/1 and MR/W018616/1) to PJT. NP and PJT are supported through the NIHR Biomedical Research Centre based at Imperial College Healthcare NHS Trust and Imperial College London. The views expressed in this article are those of the author(s) and do not necessarily reflect those of the NHS, NIHR, or the UK Departments of Health Funding Information: Dr Turner reports personal fees from Aimmune Therapeutics, DBV Technologies, Allergenis, UK Food Standards Agency and ILSI Europe; grants from National Institute for Health Research (NIHR)/Imperial Biomedical Research Centre, UK Medical Research Council, UK Food Standards Agency, End Allergies Together, Jon Moulton Charity Trust, outside the submitted work. Prof Halken reports speaker/chair fees from Nestlé Purina and ABIGO Pharma A/S. Dr Muraro reports speaker fees from Aimmune Therapeutics, DBV, and Nestlé Purina; and is an advisory board member/fees from Regeneron IDMC. Dr Deschildre reports personal fees from ALK, Stallergènes‐Greer, GSK, Novartis, Sanofi, Regeneron, Bohringer Ingelheim, Aimmune therapeutics, DBV technologies, Nestlé Health Science, Nutricia, outside the submitted work. Dr Ballmer‐Weber reports personal fees from ALK, Allergopharma, ThermoFisher, Menarini, Sanofi, Novartis. Prof. van Ree reports personal fees from HAL Allergy, ALK, Citeq, Angany, ThermoFisher, Reacta Healthcare, and Mission MightyMe; grants from European Commission, Dutch Science Foundation, and Health Holland, outside the submitted work. Prof. Worm declares the receipt of honoraria or consultation fees by the following companies: ALK‐Abelló Arzneimittel GmbH, Mylan Germany GmbH, Leo Pharma GmbH, Sanofi‐Aventis Deutschland GmbH, Regeneron Pharmaceuticals, DBV Technologies S.A, Stallergenes GmbH, HAL Allergie GmbH, Allergopharma GmbH & Co.KG, Bencard Allergie GmbH, Aimmune Therapeutics UK Limited, Actelion Pharmaceuticals Deutschland GmbH, Novartis AG, Biotest AG., AbbVie Deutschland GmbH & Co. KG and Lilly Deutschland GmbH, outside the submitted work. Prof Zuberbier reports personal fees from Bayer, FAES, Novartis, Henkel, AstraZeneca, AbbVie, ALK, Almirall, Astellas, Bencard, Berlin Chemie, HAL, Leti, Meda, Menarini, Merck, MSD, Pfizer, Sanofi, Stallergenes, Takeda, Teva, UCB, Henkel, Kryolan, L’Oréal, outside the submitted work. Prof Roberts reports grants from UK Food Standards Agency, DBV and the European Union. The other authors have no relevant conflicts of interest to declare. Funding Information: This review was conducted as part of the development of food allergy guidelines for GALEN, where contributors volunteered their time. This research was part‐funded by the UK Medical Research Council (grant references MR/K010468/1 and MR/W018616/1) to PJT. NP and PJT are supported through the NIHR Biomedical Research Centre based at Imperial College Healthcare NHS Trust and Imperial College London. The views expressed in this article are those of the author(s) and do not necessarily reflect those of the NHS, NIHR, or the UK Departments of Health 2 Publisher Copyright: © 2022 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
Keywords: anaphylaxis, biomarkers, food allergy, risk assessment, severity

Identifiers

Local EPrints ID: 457159
URI: http://eprints.soton.ac.uk/id/eprint/457159
ISSN: 0105-4538
PURE UUID: 017b2f0c-f20b-41da-b480-99c57bc6ef11
ORCID for Graham Roberts: ORCID iD orcid.org/0000-0003-2252-1248

Catalogue record

Date deposited: 25 May 2022 16:40
Last modified: 17 Mar 2024 03:02

Export record

Altmetrics

Contributors

Author: Paul J Turner
Author: Stefania Arasi
Author: Barbara Ballmer-Weber
Author: Alessia Baseggio Conrado
Author: Antoine Deschildre
Author: Jennifer Gerdts
Author: Susanne Halken
Author: Antonella Muraro
Author: Nandinee Patel
Author: Ronald Van Ree
Author: Debra de Silva
Author: Margitta Worm
Author: Torsten Zuberbier
Author: Graham Roberts ORCID iD
Corporate Author: Global Allergy, Asthma European Network (GA2LEN) Food Allergy Guideline Group

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×